科研
教育
登录
CN
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
Qi-Xang Li has not added Biography.
If you are Qi-Xang Li and would like to personalize this page please email our Author Liaison for assistance.
Discovery of 2-arylamino-4-(1-methyl-3-isopropylsulfonyl-4-pyrazol-amino)pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Bioorganic & medicinal chemistry letters Jun, 2015 | Pubmed ID: 26130408
Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Bioorganic & medicinal chemistry letters Apr, 2016 | Pubmed ID: 26979157
Molecular Pathology of Patient Tumors, Patient-Derived Xenografts, and Cancer Cell Lines.
Cancer research 08, 2016 | Pubmed ID: 27325646
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
Molecular cancer therapeutics 04, 2017 | Pubmed ID: 27903750
Experimental animal modeling for immuno-oncology.
Pharmacology & therapeutics May, 2017 | Pubmed ID: 28167217
EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab.
Oncology reports Oct, 2017 | Pubmed ID: 28849161
Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Molecular medicine reports Apr, 2018 | Pubmed ID: 29484394
Crown Bioscience Inc.
Peking University
Xiaoyu An*,1,2,
Xuesong Ouyang*,1,
Hui Zhang1,
Tingting Li1,
Yu-yang Huang1,
Zhiyuan Li1,
Demin Zhou2,
Qi-Xang Li1,2
1, Crown Bioscience Inc.,
2State Key Laboratory of Natural and Biomimetic Drugs, Peking University
政策
使用条款
隐私
联系我们
向图书馆推荐
JoVE 新闻简报
JoVE Journal
技术专题合集
JoVE Encyclopedia of Experiments
档案
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
教师资源中心
发表
图书馆员
访问权限
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。